XML 40 R26.htm IDEA: XBRL DOCUMENT
v3.22.1

Strategic Agreements (Details) - USD ($) | 1 Months Ended | 3 Months Ended | 12 Months Ended
--- | --- | --- | ---
Sep. 30, 2021 | Jun. 30, 2021 | Jan. 31, 2020 | Dec. 31, 2019 | Nov. 30, 2019 | Apr. 30, 2018 | Feb. 28, 2018 | Mar. 31, 2017 | Mar. 31, 2022 | Sep. 30, 2021 | Mar. 31, 2021 | Dec. 31, 2021 | Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
License fee |  |  |  |  |  |  |  |  | $ 25,000 |  | $ 25,000 |  |
Accrued expenses |  |  |  |  |  |  |  |  | 3,537,856 |  |  | $ 3,136,244 |
Payment of additional consideration |  |  |  |  |  |  |  |  | 46,500,000 |  |  |  |
Microchips Biotech, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Asset acquisition, contingent consideration |  |  |  |  |  |  |  |  |  |  |  |  | $ 50,000
Common stock issued to microchips capital stock holders (in shares) | 700,000 |  |  |  |  |  |  |  |  |  |  |  |
Business acquisition transaction value |  |  |  |  | $ 2,400,000 |  |  |  |  |  |  |  |
Business combination shares issued (in usd per share) |  |  |  |  | $ 0.79 |  |  |  |  |  |  |  |
Cash and cash equivalents |  |  |  |  | $ 6,100,000 |  |  |  |  |  |  |  |
Contingent consideration, liability |  |  |  |  | 3,500,000 |  |  |  |  |  |  |  |
Current portion of contingent consideration |  | $ 1,000,000 |  |  | 1,000,000 |  |  |  |  |  |  |  |
Potential additional consideration payable |  | 1,250,000 |  |  |  |  |  |  |  |  |  |  |
Accrued expenses |  |  |  |  |  |  |  |  | 250,000 |  |  | 250,000 |
Cash paid to stockholders' representative | $ 75,000 |  |  |  |  |  |  |  |  |  |  |  |
Payment of additional consideration |  | $ 1,250,000 |  |  |  |  |  |  |  |  |  |  |
Microchips Biotech, Inc. | Upon Achievement of Specified Development and Regulatory Milestones |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments |  |  |  |  | 46,500,000 |  |  |  |  |  |  |  |
Current portion of contingent consideration |  |  |  |  | 55,000,000 |  |  |  |  |  |  |  |
Microchips Biotech, Inc. | Research and development |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Business acquisition transaction value |  |  |  |  | $ 202,000 |  |  |  |  |  |  |  |
Microchips Biotech, Inc. | Common stock |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock issued to microchips capital stock holders (in shares) |  |  |  |  | 3,000,000 |  |  |  |  |  |  |  |
ADVA Tec Agreement | Upon Achievement of Specified Development and Regulatory Milestones |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments |  |  |  |  |  |  |  | $ 2,500,000 |  |  |  |  |
Maximum | ADVA Tec Agreement |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of royalty rate |  |  |  |  |  |  |  | 10.00% |  |  |  |  |
Maximum | ADVA Tec Agreement | Upon Achievement of Specified Development and Regulatory Milestones |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments |  |  |  |  |  |  |  | $ 14,600,000 |  |  |  |  |
Minimum | ADVA Tec Agreement |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of royalty rate |  |  |  |  |  |  |  | 1.00% |  |  |  |  |
MilanaPharm | Upon Achievement of Specified Development and Regulatory Milestones |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment paid in common stock |  |  |  |  |  |  |  |  | $ 50,000,000 |  |  |  |
Bayer Healthcare License Agreement |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment paid in common stock |  |  | $ 310,000,000 |  |  |  |  |  |  |  |  |  |
Upfront license fee paid |  |  | 1,000,000 |  |  |  |  |  |  |  |  |  |
Revenue from grant for notice of award |  |  | $ 20,000,000 |  |  |  |  |  |  |  |  |  |
Initial term of license agreement |  |  | 15 years |  |  |  |  |  |  |  |  |  |
Licensing Agreements | ADVA Tec Agreement | Upon Reaching Certain Worldwide Net Sales Milestones |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments term |  |  |  |  |  |  |  | 3 years |  |  |  |  |
Milestone payments |  |  |  |  |  |  |  | $ 20,000,000 |  |  |  |  |
Licensing Agreements | MilanaPharm |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment paid in common stock |  |  |  |  |  |  |  |  |  |  | $ 1,000,000 | 250,000 |
License fee |  |  |  | $ 235,000 |  |  |  |  |  |  |  |  |
License fee to be paid upon contingency |  |  |  |  |  |  |  |  |  |  |  |  | 110,000
Royalty agreement term |  |  |  |  |  |  |  |  | 10 years |  |  |  |
License agreement termination periodic discontinued sale of product |  |  |  | 60 days |  |  |  |  |  |  |  |  |
License agreement termination period due to performance failure |  |  |  | 120 days |  |  |  |  |  |  |  |  |
Certain clinical and regulatory development milestone payments |  |  |  | 90 days |  |  |  |  |  |  |  |  |
Licensing Agreements | MilanaPharm | Upon Achieving Certain Development Milestones | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment paid in common stock |  |  |  | $ 300,000 |  |  |  |  |  |  |  |  |
Licensing Agreements | MilanaPharm | Upon Achieving Certain Commercial Milestones |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment paid in common stock |  |  |  |  |  |  |  |  |  |  |  | 750,000 | 100,000
Licensing Agreements | MilanaPharm | Upon Achieving Certain Commercial Milestones | Upon Achievement of Specified Development and Regulatory Milestones |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment paid in common stock |  |  |  |  |  |  |  |  |  |  |  | $ 200,000 |
Licensing Agreements | MilanaPharm | Upon Achieving Certain Commercial Milestones | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment paid in common stock |  |  |  |  |  |  |  |  | $ 500,000 |  |  |  |
Licensing Agreements | MilanaPharm | Licensed Product or Process for Vaginal or Urological Use |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment paid in common stock |  |  |  |  |  |  |  |  | 250,000 |  |  |  |
Assignment Agreement |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
License fee |  |  |  | 512,500 |  |  |  |  |  |  |  |  |
Assignment Agreement | Hammock Pharmaceuticals, Inc |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
License fee to be paid upon contingency |  |  |  |  |  |  |  |  |  |  |  |  | $ 137,500
Assignment Agreement | Hammock Pharmaceuticals, Inc | Upon Achieving Certain Clinical and Regulatory Development Milestones | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment paid in common stock |  |  |  | $ 1,100,000 |  |  |  |  |  |  |  |  |
License and Collaboration Agreement | Strategic Science and Technologies D Limited Liability Company and Strategic Science Technologies Limited Liability Company |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of rights to inventions by employees under license agreement |  |  |  |  |  |  | 50.00% |  |  |  |  |  |
License and Collaboration Agreement | Strategic Science and Technologies D Limited Liability Company and Strategic Science Technologies Limited Liability Company | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment paid in common stock |  |  |  |  |  |  | $ 18,000,000 |  |  |  |  |  |
License and Collaboration Agreement | Strategic Science and Technologies D Limited Liability Company and Strategic Science Technologies Limited Liability Company | Minimum |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment paid in common stock |  |  |  |  |  |  | 500,000 |  |  |  |  |  |
License and Collaboration Agreement | Strategic Science and Technologies D Limited Liability Company and Strategic Science Technologies Limited Liability Company | Upon Achieving Certain Commercial Milestones | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment paid in common stock |  |  |  |  |  |  | 100,000,000 |  |  |  |  |  |
License and Collaboration Agreement | Strategic Science and Technologies D Limited Liability Company and Strategic Science Technologies Limited Liability Company | Upon Achieving Certain Commercial Milestones | Minimum |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment paid in common stock |  |  |  |  |  |  | $ 10,000,000 |  |  |  |  |  |
Juniper Pharmaceuticals, Inc |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront license fee paid |  |  |  |  |  | $ 250,000 |  |  |  |  |  |  |
Potential annual license maintenance fee, payments in year one |  |  |  |  |  | 50,000 |  |  |  |  |  |  |
Potential annual license maintenance fee payments, thereafter |  |  |  |  |  | 100,000 |  |  |  |  |  |  |
Juniper Pharmaceuticals, Inc | Clinical and Regulatory Milestones |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum potential milestone payments |  |  |  |  |  | 13,500,000 |  |  |  |  |  |  |
Juniper Pharmaceuticals, Inc | Sales Milestones |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum potential milestone payments |  |  |  |  |  | $ 30,300,000 |  |  |  |  |  |  |
Organon |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront license fee paid |  |  |  |  |  |  |  |  | 10,000,000 |  |  |  |
Milestone payment paid in common stock |  |  |  |  |  |  |  |  | 182,500,000 |  |  |  |
First commercial sale amount |  |  |  |  |  |  |  |  | 2,500,000 |  |  |  |
Sales based milestones amount |  |  |  |  |  |  |  |  | $ 180,000,000 |  |  |  |
Milestone payments term |  |  |  |  |  |  |  |  | 10 years |  |  |  |
Catalent and MilanaPharm |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Annual maintenance fee |  |  |  |  |  |  |  |  |  | $ 100,000 |  |  |
Net amount payable |  |  |  |  |  |  |  |  | $ 900,000 |  |  |  |
Catalent and MilanaPharm | Licensing Agreements |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment paid in common stock |  |  |  |  |  |  |  |  |  | $ 1,000,000 |  |  |

X
- Definition Asset Acquisition, Contingent Consideration + References No definition available. + Details
Name: | dare_AssetAcquisitionContingentConsideration
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Asset Acquisition, Contingent Consideration, Current + References No definition available. + Details
Name: | dare_AssetAcquisitionContingentConsiderationCurrent
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Business combination reverse merger recognized identifiable assets acquired and liabilities assumed cash and equivalents. + References No definition available. + Details
Name: | dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition License Agreement, Initial Term + References No definition available. + Details
Name: | dare_LicenseAgreementInitialTerm
Namespace Prefix: | dare_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition License Agreement Notice Period Of Termination + References No definition available. + Details
Name: | dare_LicenseAgreementNoticePeriodOfTermination
Namespace Prefix: | dare_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition License agreement, termination period due to performance failure. + References No definition available. + Details
Name: | dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure
Namespace Prefix: | dare_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition License Agreement Termination Periodic Discontinued Sale Of Product + References No definition available. + Details
Name: | dare_LicenseAgreementTerminationPeriodicDiscontinuedSaleOfProduct
Namespace Prefix: | dare_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition License Fee + References No definition available. + Details
Name: | dare_LicenseFee
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition License Fee, To Be Paid Upon Contingency + References No definition available. + Details
Name: | dare_LicenseFeeToBePaidUponContingency
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Maximum Potential Milestone Payments + References No definition available. + Details
Name: | dare_MaximumPotentialMilestonePayments
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone payments, contingent amount. + References No definition available. + Details
Name: | dare_MilestonePaymentsContingentAmount
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Milestone Payments, Contingent Amount, First Commercial Sale Amount + References No definition available. + Details
Name: | dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Milestone Payments, Contingent Amount Payable, Net + References No definition available. + Details
Name: | dare_MilestonePaymentsContingentAmountPayableNet
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Milestone Payments, Contingent Amount, Sales Based Milestones Amount + References No definition available. + Details
Name: | dare_MilestonePaymentsContingentAmountSalesBasedMilestonesAmount
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Milestone Payments, Term + References No definition available. + Details
Name: | dare_MilestonePaymentsTerm
Namespace Prefix: | dare_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Payment of Additional Consideration in Business Combination + References No definition available. + Details
Name: | dare_PaymentOfAdditionalConsiderationInBusinessCombination
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payments to Stockholders' Representative in Business Combination + References No definition available. + Details
Name: | dare_PaymentsToStockholdersRepresentativeInBusinessCombination
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage of rights to inventions by employees under license agreement. + References No definition available. + Details
Name: | dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement
Namespace Prefix: | dare_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of royalty rate. + References No definition available. + Details
Name: | dare_PercentageOfRoyaltyRate
Namespace Prefix: | dare_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Potential Annual License Maintenance Fee, Payments In Year One + References No definition available. + Details
Name: | dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Potential Annual License Maintenance Fee Payments, Thereafter + References No definition available. + Details
Name: | dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Research and development milestone payment. + References No definition available. + Details
Name: | dare_ResearchAndDevelopmentMilestonePayment
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Royalty Agreement, Term + References No definition available. + Details
Name: | dare_RoyaltyAgreementTerm
Namespace Prefix: | dare_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront License Fee, Amount Paid + References No definition available. + Details
Name: | dare_UpfrontLicenseFeeAmountPaid
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Upfront License Fee Paid + References No definition available. + Details
Name: | dare_UpfrontLicenseFeePaid
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_AccruedLiabilitiesCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b)(4) -URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479 + Details
Name: | us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Number of shares of equity interests issued or issuable to acquire entity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b)(4) -URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479 + Details
Name: | us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination. + References No definition available. + Details
Name: | us-gaap_BusinessAcquisitionSharePrice
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c)(1) -URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 35 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Cost of maintenance incurred and directly related to good produced and service rendered. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(b)(2)) -URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227 + Details
Name: | us-gaap_CostMaintenance
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Describes the maximum potential amount of consideration, undiscounted, that could be transferred under the registration payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=99383193&loc=d3e16207-108621 + Details
Name: | us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=dare_MicrochipsBiotechInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_ADVATecAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_MilanaPharmMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=dare_BayerHealthcareLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dare_UponReachingCertainWorldwideNetSalesMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=dare_UponAchievingCertainDevelopmentMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=dare_UponAchievingCertainCommercialMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=dare_LicensedProductOrProcessForVaginalOrUrologicalUseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=dare_AssignmentAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_HammockPharmaceuticalsInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=dare_LicenseAndCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=dare_JuniperPharmaceuticalsInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_ClinicalAndRegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_SalesMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=dare_OrganonMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=dare_CatalentAndMilanaPharmMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |